On August 6, 2026 Lantheus Holdings, Inc. (Lantheus or the Company) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, reported financial results for its second quarter ended June 30, 2026.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

In addition, and as previously announced, Lantheus entered into a definitive agreement on August 3, 2026 to merge with Curium under which Curium US Holdings LLC will acquire all outstanding shares of Lantheus for $102.50 per share in cash at closing, plus non-transferable Contingent Value Rights ("CVRs") providing for up to $12.00 per share in potential additional cash payments, subject to achievement of specified commercial milestones for Lantheus’ products through 2030. The transaction represents a total per share consideration of up to $114.50 and a total transaction value of up to approximately $8.0 billion. Together, Curium and Lantheus are positioned to create a radiopharmaceutical company spanning diagnostics and therapeutics, with the infrastructure and capabilities to serve patients in more than 70 countries. The Board of Directors of Lantheus has unanimously approved the transaction. Additional information regarding the transaction is available in the Company’s Current Report on Form 8-K filed with the SEC on August 4, 2026.

In connection with the pending transaction, Lantheus is suspending its previously issued full year 2026 financial guidance and will not be hosting a conference call in connection with its second quarter 2026 results.

Summary Financial Results

Three Months Ended
June 30,
(in millions, except per share data – unaudited) 2026 2025 % Change
Worldwide revenue $ 388.2 $ 378.0 2.7 %
GAAP net income $ 75.0 $ 78.8 (4.7 %)
GAAP fully diluted earnings per share $ 1.11 $ 1.12 (0.9 %)
Adjusted net income (non-GAAP) $ 104.9 $ 110.6 (5.1 %)
Adjusted fully diluted earnings per share (non-GAAP) $ 1.55 $ 1.57 (1.3 %)

Second Quarter 2026

Worldwide revenue increased 2.7% to $388.2 million compared to the same period in 2025.
Sales of PYLARIFY were $240.4 million, a decrease of 4.1%.
Sales of Neuraceq were $39.6 million.
Sales of DEFINITY were $88.3 million, an increase of 5.2%.
Operating income increased 13.9% to $100.2 million. Adjusted operating income (non-GAAP) decreased 6.9% to $142.0 million.
Fully diluted earnings per share decreased 0.9% to $1.11, compared to fully diluted earnings per share of $1.12 in the prior year period. Adjusted fully diluted earnings per share (non-GAAP) decreased 1.3% to $1.55, compared to $1.57 in the prior year period.
Net cash provided by operating activities and free cash flow were $92.2 million and $89.9 million, respectively.
Balance Sheet

At June 30, 2026, the Company’s cash and cash equivalents were $593.3 million, compared to $359.1 million at December 31, 2025.
The Company currently has access to up to $750.0 million from a revolving line of credit.

(Press release, Lantheus, AUG 6, 2026, View Source [SID1234669846])